Navigation Links
New Drug Application for Ibrutinib Submitted to the U.S. FDA
Date:7/10/2013

yments, and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "goal", "should", "would", "project", "plan", "predict", "intend", "target" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance, expected liquidity or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and uncertainties that may affect o
'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
2. Ventana Receives FDA Clearance for p53 (DO-7) Image Analysis and Digital Read Applications
3. Bio-AMD, Inc.; Patent Application for Cartridge Test Cap
4. Global Ablation Technologies Market (2011-2016) - By Application and Devices in Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Electrical, Light/Laser and Hydromechanical - Global Trends & Competitive Analysis
5. Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing Applications
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
8. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
9. Philips demonstrates innovations in nuclear medicine imaging with a comprehensive portfolio of NM applications for IntelliSpace Portal
10. Clinical Safety Data for ChromaDex®s Patented pTeroPure® (pterostilbene) Released at 6th World Congress on Polyphenols Applications in Paris
11. UltraTape announces Cleanroom Labels for Cryogenic Laboratory applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Calif. , March 2, 2015 Isis Pharmaceuticals, ... has earned a $15 million milestone payment from GSK related ... in patients with familial amyloid polyneuropathy (FAP).  ... with ISIS-TTR Rx , and plan to report data from ... have completed the fifteen months of dosing and are now ...
(Date:3/2/2015)... BETHESDA, Md. , March 2, 2015 ... on treating and preventing autoimmune diseases, announced today that ... (AMG 714) from Amgen (NASDAQ: AMGN ). ... has the rights to develop, manufacture and commercialize AMG ... . Concurrently, Amgen has been granted an exclusive ...
(Date:3/2/2015)... Texas , March 2, 2015   Lexicon ... biopharmaceutical company focused on developing breakthrough treatments for human ... 2014 financial results on Wednesday, March 4, 2015 before ... conference call and webcast to discuss clinical development progress ... end of 2014 at 10:00 a.m. Eastern Time on ...
Breaking Medicine Technology:Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx 2Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx 3Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 2Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 3Lexicon To Report Fourth Quarter And Year End 2014 Financial Results On March 4, 2015 2
... plc (Nasdaq: JAZZ ) today announced several ... company,s leadership team. The appointments include: ... company and will serve as general counsel and an ... in March.  Ms. Hooper is currently a partner at ...
... Sinovac Biotech Ltd. (Nasdaq: SVA ), a leading ... a letter dated January 18, 2012 from The Nasdaq Stock ... from the Company,s Board of Directors effective January 4, 2012, ... Nasdaq,s requirement that its audit committee consists of at least ...
Cached Medicine Technology:Jazz Pharmaceuticals plc Announces New Executive Appointments 2Sinovac Receives Nasdaq Deficiency Letter Regarding Audit Committee Requirement 2
(Date:3/2/2015)... California (PRWEB) March 02, 2015 Final ... of the TranStatic Volume 2 from Pixel Film Studios. , ... made exclusively for FCPX,” said Christina Austin, CEO of Pixel ... have in any Final Cut Pro X editors toolbox.” , ... to the next with media altering static scrambling effects from ...
(Date:3/1/2015)... Women’s Excellence is pleased to announce ... on their website. There are over 75 terms and phrases ... , “This gives our patients a better understanding of what ... they may not understand. With this resource, our patients are ... and find terms and phrases that they may not remember or ...
(Date:3/1/2015)... March 01, 2015 A federal ... http://www.consumerinjurylawyers.com/wright-profemur-hip-replacement ) scheduled to go to trial in ... a witness to provide testimony regarding the role ... of the Profemur device, Bernstein Liebhard LLP comments. ... Court, Northern District of Iowa on February 25th, ...
(Date:3/1/2015)... “ The Barrel Mill ” was featured ... takes a look at the latest and coolest technology products ... NewsWatch and a technology expert, conducted the review and shared ... drinks. , According to Home Distillation of Alcohol, it's understood ... there’s a pretty cool product that’ll help anyone achieve a ...
(Date:2/28/2015)... Heart diseases are on the rise in India. ... population and 5 percent of rural adult population suffer ... of them require specialized investigation and treatment to prevent ... (CVD). , A division of Indian Business News Agency ... “Indian Coronary Stent Market Forecast to 2019”. The new ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios released the TranStatic Volume 2 plugin for Final Cut Pro X today 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3
... ... weight loss can be with HCG Diet Drops , ... (PRWEB) June 14, 2010 -- It is no secret that obesity has reached epidemic ... suffering from health problems as a result of the extra pounds. , , ,But thanks ...
... CerMedia ... the Cell-Pore product group previously owned and operated by NanoDynamics, Inc. ... Buffalo, NY (PRWEB) ... of the principal manufacturing and production assets, inventory and certain information of the Cell-Pore ...
... ... specialist in cosmetic, facial plastic, and reconstructive surgery, understands that women need options. With ... patients an alternative method to breast implant surgery. Natural breast augmentation allows patients the ... ...
... N.C. Monday, June 14, 2010 A new study ... shows that millions of cancer survivors are forgoing needed medical ... today in CANCER, a peer-reviewed journal of the ... long-term health and well-being of cancer survivors could suffer because ...
... ... medical and financial benefits. The Sit&SipTM bottle is engineered for easy and healthy performance. ... ... 15 - 20 million visits to the doctor each year in the U.S. Acute ...
... ... , ... The Primax Electronic Cigarette System is now available from Primevapor.com., , ,Primevapor has combined a ... These cartridges not only produce more flavor and more vapor, but use US manufactured, vegetable ...
Cached Medicine News:Health News:Thousands Drop The Weight For Good with HCG Diet Drops 2Health News:CerMedia Completes Purchase of Cell-Pore Principal Assets from NanoDynamics 2Health News:Del Mar Plastic Surgeon Dr. Maurice Sherman Now Offering Natural Breast Implant Alternatives 2Health News:Cost concerns prevent many cancer survivors from getting medical care 2Health News:Ear Infection is the Most Common Reason Why an American Child Sees the Doctor 2Health News:Ear Infection is the Most Common Reason Why an American Child Sees the Doctor 3Health News:Electronic Cigarettes Are Better Than Ever 2
The VPAP III is a complete system solution for sleep-disordered breathing (SDB), providing comfortable and effective bilevel treatment. The VPAP III is an effective business solution for clinicians, ...
... for the Separation and Measurement of ... Subfractions, ,The Lipoprint System is a ... components which are not routinely tested ... provides detailed results within the subfractions ...
... high resolution diagnostic test for cholesterol components which ... test procedure is simple and can be done ... is clearly flagged. A color coded profile is ... in red and the good HDL in green. ...
... Ammonia/Alcohol Control is intended as ... ammonia and ethanol assay methods. ... targeted at clinically significant levels ... values are provided for the ...
Medicine Products: